Cargando…

A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study

PURPOSE: To develop and validate a PI-RADS-based nomogram for predicting the probability of clinically significant prostate cancer (csPCa) at initial prostate biopsy. PATIENTS AND METHODS: From February 2015 to October 2018, 573 consecutive patients made up the development cohort (DC), and another 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yueyue, Zhu, Guiqi, Zhao, Wenlu, Wei, Chaogang, Chen, Tong, Ma, Qi, Zhang, Yongsheng, Xue, Boxin, Shen, Junkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245434/ https://www.ncbi.nlm.nih.gov/pubmed/32547200 http://dx.doi.org/10.2147/CMAR.S250633

Ejemplares similares

A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone
por: Wei, Chaogang, et al.
Publicado: (2021)

Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy
por: Yang, Shuo, et al.
Publicado: (2020)

Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
por: Chen, Tong, et al.
Publicado: (2018)

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
por: Chen, Tong, et al.
Publicado: (2022)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
por: Li, Tianping, et al.
Publicado: (2022)

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study
por: Zhou, Yongheng, et al.
Publicado: (2023)

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells
por: Wei, Chaogang, et al.
Publicado: (2018)

A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients
por: Hu, Beibei, et al.
Publicado: (2023)

Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
por: Zhang, Yu, et al.
Publicado: (2018)

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

PI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
por: Camacho, Andrés, et al.
Publicado: (2023)

Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
por: Wang, Yunhan, et al.
Publicado: (2023)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
por: Viana, Publio Cesar Cavalcanti, et al.
Publicado: (2019)

Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study
por: Jin, Pengfei, et al.
Publicado: (2023)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Natale, Caleb, et al.
Publicado: (2021)

An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study
por: Hiremath, Amogh, et al.
Publicado: (2021)

Standardization of Multiparametric Prostate MR Imaging Using PI-RADS
por: Bomers, Joyce G. R., et al.
Publicado: (2014)

Impact of PI-RADS v2 on indication of prostate biopsy
por: Rozas, George de Queiroz, et al.
Publicado: (2019)

Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies
por: Wang, Changming, et al.
Publicado: (2022)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

Development and external validation of a novel nomogram to predict prostate cancer in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions
por: Hu, Can, et al.
Publicado: (2022)

Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
por: Zhang, Yongsheng, et al.
Publicado: (2020)

Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions
por: Brancato, Valentina, et al.
Publicado: (2021)

Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study
por: Zhao, Litao, et al.
Publicado: (2022)

Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study
por: Cai, Guan-Hui, et al.
Publicado: (2021)

Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI‐RADS 3–5 regions of interest
por: Stone, Nelson, et al.
Publicado: (2021)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram
por: Jing, Guodong, et al.
Publicado: (2022)

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone
por: Wen, Jing, et al.
Publicado: (2022)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

Prospective evaluation of PI-RADS v2 and quantitative MRI for clinically significant prostate cancer detection in Indian men – East meets West
por: Kubihal, Vijay, et al.
Publicado: (2022)

Prostate MRI based on PI-RADS version 2: how we review and report
por: Steiger, Philipp, et al.
Publicado: (2016)

The role of different PI-RADS versions in prostate multiparametric magnetic resonance tomography assessment
por: Aliukonis, Paulius, et al.
Publicado: (2017)

A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage
por: He, Wei, et al.
Publicado: (2011)

The Value of Low Prostate Imaging—Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies
por: Kim, Dong-Soo, et al.
Publicado: (2021)

The Impact of Prostate Volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a Real-World Setting
por: Volz, Yannic, et al.
Publicado: (2023)

Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

The multiparametric prostate resonance imaging with the prostate imaging-reporting and data system (PI-RADS): the state of art of prostate cancer diagnosis
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_60au8r0qt81p14l822632jukb1